FY2024 EPS Estimates for Personalis Reduced by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Personalis in a research note issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.36) for the year, down from their previous forecast of ($1.29). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.

Personalis (NASDAQ:PSNL) last announced its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. During the same period in the prior year, the business posted ($0.51) EPS.

PSNL has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and issued a $7.25 price target on shares of Personalis in a research note on Wednesday, January 8th. Lake Street Capital lifted their target price on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th.

Personalis Price Performance

Shares of PSNL stock opened at $5.44 on Wednesday. Personalis has a 12 month low of $1.12 and a 12 month high of $7.20. The company’s fifty day simple moving average is $4.90 and its 200-day simple moving average is $4.75.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC increased its position in Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after buying an additional 723,637 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Personalis by 20.0% during the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after acquiring an additional 83,068 shares during the period. abrdn plc acquired a new position in shares of Personalis during the 4th quarter worth approximately $1,722,000. State Street Corp increased its holdings in shares of Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after acquiring an additional 44,900 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Personalis in the 3rd quarter valued at $897,000. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.